SOPHiA GENETICS’ Post

Connected-Pathology can help you with your preclinical oncology studies in a variety of ways. Please see this post to learn more and reach out to me in case there is any questions. #histopathology #immunohistochemistry #multiplexif #mif #oncology #tumor_pathology #assaydevelopment #leadoptimization #targetvalidation #veterinarypathologist InnoSer https://lnkd.in/eiDFKzqk

IOCB Tech has opened a high-tech center for new medicines in #Prague. Discoveries from Ústav organické chemie a biochemie AV ČR now have a greater chance of making it into practice, and patients with previously untreatable diseases now have stronger hope of effective therapy. This is because a unique translational center, combining science and its commercial application - #Pharmtheon - is now operational in #Czechia. The first project to be developed at the center is the development of compounds that reduce the frequency of mutations in cancer cells. These mutations are the reason for the development of resistance to some drugs used in the chemotherapy of oncology patients. #drugdiscovery #hightech #labs

1st data from TSO500+HRD testing from Slovakia! We are bringing you the results from the pilot study of revealing the genetic essence of #cancer through #CGP and #HRD analysis based on #illumina solution. This pilot study was conducted in cooperation with our long-term partner, Unilabs Kosice. We prepared for you an interesting interview with Dr. Verebova about her laboratory and the first data using the Illumina #TSO500_HRD solution. Let's look at the top points: → The Laboratory of Medical Genetics in Kosice has been dedicated to diagnosing #hereditary #tumor syndromes for over 10 years. From 2015, it was expanded to the analysis of #somatic mutations in various types of tumors → #CGP minimizes the amount of necessary input material, maximizes the ability to identify significant genomic changes, and shortens the total time of the examination process, which can help  to improve the management of #oncology patients → Current #ESMO guidelines recommend considering #HRD testing to identify patients benefiting from #PARPi treatment. → 16 samples of patients with high-grade #ovarian_cancer who were #BRCA1 and #BRCA2 wild type were included in the pilot study. According to the initial results, in 37.5% of samples detected positive #HRD_status based on the #genomic_instability_score (GIS≥42). GeneTiCA Group congratulates the laboratory for the first successful results, and we are ready to support you in implementing this methodology into routine practice.   GeneTiCA Group; your partner for innovative approaches.

Did you know that AI models have been developed to predict the IDH biomarker status in glioma? Given the anticipated imminent approval of vorasidenib, an IDH-targeted treatment granted fast fast-track designation by the FDA for low-grade glioma, such AI models offer a valuable, non-invasive, and timely alternative to molecular testing. #aiforgood #oncology #technology

Congratulations to Renato Ostuni for being awarded the competitive European Research Council (ERC) Proof of Concept Grant! This success adds up to the other two ERC financings won by Renato - the Starting and the Consolidator grants in 2017 and 2022. The project aims at addressing the major unmet need to develop personalized treatments for patients with intraductal papillary mucinous neoplasms (IPMNs) – known precursor lesions of Pancreatic Ductal Adenocarcinoma (PDAC) that is one of the most frequent causes of cancer-related death worldwide. Renato and his team will build on the gene signature identified in pre-neoplastic cells thanks to the ERC-StG and will test it as biomarker for PDAC in IPMN patients. Successful validation of the signature should advance early #pancreaticcancer detection thus providing benefits for the clinical management of patients.

This weeks Cancer Genomics Consult, a pediatric case of neuroblastoma with a possible driver gene. We'd welcome your thoughts on the questions from the oncologist and will post our experts' interpretation shortly. #precisiononcology #cancergenomics #decisionsupport #patientadvocacy

EXPERT INSIGHTS: “Between 2007 and 2017, India conducted only 350 interventional cancer trials, a significant contrast to the 2066 trials registered in the US in 2017 alone." Kausik Maiti, MD, Executive Director, Medical Sciences at Parexel India explains how this stark difference underscores the urgency for India to accelerate and expand its research efforts in cancer.” Access March-April 2024 issue of #BioVoiceNews #eMagazine:  tinyurl.com/5xhz9zc7 #bioscience #biotech #biopharma #cro #clinicaltrials #clinicalresearch #researchandinnovation #insights #experts #magazine #news #India 

Today, the FNIH Biomarkers Consortium announces the launch of a significant project to develop and validate blood-based biomarkers for predicting progression to multiple myeloma. This collaborative initiative brings together critical resources and stakeholders from the public sector, the private sector, and academia. By creating less invasive and more accurate prediction methods, we aim to enable earlier treatment and improve patient outcomes.    Watch to hear more about the project from investigators Irene Ghobrial, MD, Professor of Medicine, Dana-Farber Cancer Institute, and Bruno Paiva, PhD, Co-director, Flow Cytometry Platform & Monoclonal Gammopathies Research Laboratory, University of Navarra. Learn more at fnih.org/MMyeRisk #FNIH #BridgesToBreakthroughs #Biomarkers #BiomarkersConsortium #MultipleMyeloma #CancerResearch Pfizer Regeneron AbbVie

The Athymic nude mice from Envigo ++++ were utilized to study the metastasis by targeting glycerophospholipid synthesis through HIF1α or G3P (glycerol-3-phosphate) acyltransferase 3 knockdown in an adipose-rich tumor microenvironment, thereby suggesting a promising strategy for inhibiting metastasis. This breakthrough study identified the role of adipocytes in driving ovarian cancer metastasis by redirecting glucose towards G3P biosynthesis, facilitated by HIF1α regulation. Please read the following article for more details – https://lnkd.in/gyDRwB5B To understand more on the Athymic nude mice, visit - https://lnkd.in/gyxA5XWw GV Safety Assessment Platform (GVSAP), a subsidiary of GV Research Platform (GVRP) is a Hyderabad based pre-clinical CRO and an authorized breeder and distributor of Envigo ++++'s (an Inotiv company) research models & services in India. Reach us for more information: 📨: info@gvrp.in 🌐: www.gvrp.in #animalmodel #drugdiscovery #lifesciences #research #researchmodels #mousestrains #drugdevelopment #gvrp #envigo #cro #manuscript #invivostudies

a great scientific achievement with renowned experts in the field which we leveraged to develop a fantastic AI algorithm for one of the harder tasks for pathologists: CPS scoring of PD-L1 stained tissues accurately, reproducibly and comparably happy to tell you more and give you a demo - just drop me DM #aihealthcare #biomarker #novelbiomarker #pharmaceuticals #biotech #digitalpathology #pathology #research